|Day Low/High||42.47 / 44.24|
|52 Wk Low/High||37.59 / 55.51|
Stocks rally as investors continue to analyze Federal Reserve Chair Janet Yellen's Friday speech.
And how to play the fallout on related stocks.
Here's a technical look at how to trade some of the most active stocks on the market right now.
Past price action does not guarantee future price action.
Jim Cramer explains that a lack of competition is largely to blame for Mylan's (MYL) skyrocketing price of its EpiPen treatment.
The drugmaker says it will launch the product in 'several weeks' at a list price of $300 per two-park carton.
Mylan (MYL) will soon release a less expensive, generic version of its EpiPen treatment following outcry of the branded version's $600 price tag.
Mylan seeks to quell public outrage of its EpiPen Pricing with a generic version of the product.
The drugmaker's shares are higher after announcing the discounted allergy treatment.
U.S. stocks are rising Monday as investors continue to digest comments from top Federal Reserve officials.
Momentum indicators are down hard, so is relative strength, while earnings were great.
U.S. stocks are higher Monday, as investors continued to digest comments on interest rates from Federal Reserve Chair Janet Yellen on Friday.
U.S. stock futures are trading flat Monday as investors continue to digest comments from top Federal Reserve officials on Friday.
Herbalife shares were climbing after Carl Icahn heated up his long-running spat with Bill Ackman.
Jim Cramer ponders the presidential campaign tradition of corporate bashing and how the stock market is more important than the Fed.
While the public seized on Mylan's price increases for EpiPens, the story of a common drug industry practice - increasing prices ahead of generics entering the market - got lost.
Pharmacy Benefit Managers (PBMs) 'operate within a sphere of secrecy,' Black Rock Pharmacy co-owner Brad Arthur told CNBC.
Mylan pushed the blame for high EpiPen prices onto PBMs Thursday, causing share prices to dip. Analysts say investors were mislead.
Pretty much every company you can think of has donated to the Clinton Foundation. So has Donald Trump. Should it matter?
The recent harsh spotlight on the sector raises the question.
Wall Street will look to comments from Fed Chair Janet Yellen on interest rates; futures are higher; Carl Icahn recently discussed selling his stake in Herbalife, a report says.
Cramer says he doesn't understand the obsession some investors have with the Federal Reserve. Forget the Fed.
Iowa Senator Charles Grassley said he'll have the conversation Mylan (MYL) CEO Heather Bresch has asked him for once she answers his letter.
The anticipation for Friday's speech from Federal Reserve Chair Janet Yellen left investors hesitant on Thursday.
The company is under public scrutiny, and has lost more than 12% of its share price so far this week.
More competition in the drug industry would prevent situations like the big price hike in Mylan's EpiPens, according to Jim Cramer.